The past 10 years-new hormones, new functions, new endocrine organs

Nature Reviews Endocrinology

Volumn 11, Issue 11, 2015, Pages 681-686

  Bouillon, Roger ^a   Drucker, Daniel J ^b   Ferrannini, Ele ^c   Grinspoon, Steven ^d   Rosen, Clifford J ^e   Zimmet, Paul ^f  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF PISA   (Italy)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Maine Medical Center Research Institute   (United States)

^f BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; HORMONE; IRISIN; LEPTIN; MYOSTATIN; OSTEOCALCIN; SOMATOMEDIN;

ADVISORY COMMITTEE; BONE; BONE REMODELING; CENTRAL NERVOUS SYSTEM; ECTOPIC ADIPOSE TISSUE; ECTOPIC TISSUE; ENDOCRINE CELL; ENDOCRINE FUNCTION; ENDOCRINE GLAND; ENDOCRINE SYSTEM; ENTEROENDOCRINE CELL; EX VIVO STUDY; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; INSULIN RESISTANCE; INTESTINAL TISSUE; INTRAABDOMINAL FAT; MUSCULOSKELETAL SYSTEM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; PANCREAS ISLET BETA CELL; PANCREAS SECRETION; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; STOMACH ACID; SYMPATHETIC TONE; ANIMAL; ENDOCRINOLOGY; GASTROINTESTINAL TRACT; MUSCULOSKELETAL FUNCTION; PATHOPHYSIOLOGY; PHYSIOLOGY; TRENDS;

ANIMALS; DIABETES MELLITUS, TYPE 2; ENDOCRINE GLANDS; ENDOCRINOLOGY; GASTROINTESTINAL TRACT; HORMONES; HUMANS; MUSCULOSKELETAL PHYSIOLOGICAL PROCESSES;

EID: 84945473213     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2015.142     Document Type: Review

References (69)

1. Dallas, S. L., Prideaux, M. & Bonewald, L. F. The osteocyte: an endocrine cell and more. Endocr. Rev. 34, 658-690 (2013).
2. Bouillon, R. et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr. Rev. 29, 726-776 (2008).
3. Quarles, L. D. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat. Rev. Endocrinol. 8, 276-286 (2012).
4. Komaba, H. & Fukagawa, M. The role of FGF23 in CKD-with or without Kloth. Nat. Rev. Nephrol. 8, 484-490 (2012).
5. Papapoulos, S. E. Anabolic bone therapies in 2014: new bone-forming treatments for osteoporosis. Nat. Rev. Endocrinol. 11, 69-70 (2015).
6. Karsenty, G. & Ferron, M. The contribution of bone to whole-organism physiology. Nature 481, 314-320 (2012).
7. Riddle, R. C. et al. Tsc2 is a molecular checkpoint controlling osteoblast development and glucose homeostasis. Mol. Cell. Biol. 34, 1850-1862 (2014).
8. Lee, N. K. et al. Endocrine regulation of energy metabolism by the skeleton. Cell 130, 456-469 (2007).
9. Oury, F. et al. Endocrine regulation of male fertility by the skeleton. Cell 144, 796-809 (2011).
10. Takayanagi, H. Osteoimmunology in 2014: two-faced immunology-from osteogenesis to bone resorption. Nat. Rev. Rheumatol. 11, 74-76 (2015).
11. Spiegelman, B. M. Banting Lecture 2012: regulation of adipogenesis: toward new therapeutics for metabolic disease. Diabetes 62, 1774-1782 (2013).
12. Pedersen, B. K. & Febbraio, M. A. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat. Rev. Endocrinol. 8, 457-465 (2012).
13. Bouillon, R. et al. Vitamin D and energy homeostasis: of mice and men. Nat. Rev. Endocrinol. 10, 79-87 (2014).
14. th edn Ch. 39 (eds Melmed, S. et al.) 1697-1718 (Elsevier Saunders, 2012).
15. Tatemoto, K. & Mutt, V. Chemical determination of polypeptide hormones. Proc. Natl Acad. Sci. USA 75, 4115-4119 (1978).
16. Bell, G. I., Sanchez-Pescador, R., Laybourn, P. J. & Najarian, R. C. Exon duplication and divergence in the human preproglucagon gene. Nature 304, 368-371 (1983).
17. Reimann, F. et al. Glucose sensing in L cells: a primary cell study. Cell Metab. 8, 532-539 (2008).
18. Habib, A. M. et al. Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology 153, 3054-3065 (2012).
19. Engelstoft, M. S., Egerod, K. L., Lund, M. L. & Schwartz, T. W. Enteroendocrine cell types revisited. Curr. Opin. Pharmacol. 13, 912-921 (2013).
20. Campbell, J. E. & Drucker, D. J. Pharmacology physiology and mechanisms of incretin hormone action. Cell Metab. 17, 819-837 (2013).
21. Drucker, D. J. & Yusta, B. Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu. Rev. Physiol. 76, 561-583 (2014).
22. Finan, B. et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat. Med. 21, 27-36 (2015).
23. Sadry, S. A. & Drucker, D. J. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat. Rev. Endocrinol. 9, 425-433 (2013).
24. Cani, P. D. et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58, 1091-1103 (2009).
25. Chimerel, C. et al. Bacterial metabolite indole modulates incretin secretion from intestinal enteroendocrine L cells. Cell Rep. 9, 1202-1208 (2014).
26. Halberg, N., Wernstedt-Asterholm, I. & Scherer, P. E. The adipocyte as an endocrine cell. Endocrinol. Metab. Clin. North Am. 37, 753-768 (2008).
27. Donath, M. Y., Böni-Schnetzler, M., Ellingsgaard, H., Halban, P. A. & Ehses, J. A. Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends Endocrinol. Metab. 21, 261-267 (2010).
28. Maresca, F. et al. Adipokines, vascular wall, and cardiovascular disease: a focused overview of the role of adipokines in the pathophysiology of cardiovascular disease. Angiology 66, 8-24 (2015).
29. Aguilar-Valles, A., Inoue, W., Rummel, C. & Luheshi, G. N. Obesity, adipokines and neuroinflammation. Neuropharmacology 96, 124-134 (2015).
30. Newgard, C. B. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab. 15, 606-614 (2012).
31. Ferrannini, E. et al. Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. Diabetes 62, 1730-1737 (2013).
32. Mezza, T. et al. Insulin resistance alters islet morphology in nondiabetic humans. Diabetes 63, 994-1007 (2014).
33. Talchai, C., Xuan, S., Lin, H. V., Sussel, L. & Accili, D. Pancreatic β-cell dedifferentiation as a mechanism of diabetic β-cell failure. Cell 150, 1223-1234 (2012).
34. Ferrannini, E. The stunned β cell: a brief history. Cell Metab. 11, 349-352 (2010).
35. Hodson, D. J. et al. Lipotoxicity disrupts incretin-regulated human β-cell connectivity. J. Clin. Invest. 123, 4182-4194 (2013).
36. Preis, S. R. et al. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. Obesity, 11, 2191-2198 (2010).
37. Rexrode, K. M. et al. Abdominal obesity and coronary heart disease in women. JAMA 280, 1843-1848 (1998).
38. Batsis, J. A. et al. Normal weight obesity and mortality in United States subjects 60 years of age (from the Third National Health and Nutrition Examination Survey). Am. J. Cardiol. 112, 1592-1598 (2013).
39. Kaess, B. M. The ratio of visceral to subcutaneous fat, a metric of body fat distribution is a unique correlate of cardiometabolic risk. Diabetologia 10, 2622-2630 (2012).
40. Falutz, J. et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J. Clin. Endocrinol. Metab. 95, 4291-4304 (2010).
41. Falutz, J. et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N. Engl. J. Med. 357, 2359-2370 (2007).
42. Makimura, H., Stanley, T., Mun, D., You, S. M. & Grinspoon, S. The effects of central adiposity on growth hormone (GH) response to GH-releasing hormone-arginine stimulation testing in men. J. Clin. Endocrinol. Metab. 93, 4254-4260 (2008).
43. Miller, K. K. et al. Truncal adiposity, relative growth hormone deficiency, and cardiovascular risk. J. Clin. Endocrinol. Metab. 90, 768-774 (2005).
44. Makimura, H. et al. Reduced growth hormone secretion is associated with increased carotid intima-media thickness in obesity. J. Clin. Endocrinol. Metab. 94, 5131-5138 (2009).
45. Koutkia, P., Meininger, G., Canavan, B., Breu, J. & Grinspoon, S. Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy. Am. J. Physiol. Endocrinol. Metab. 286, E296-E303 (2004).
46. Peino, R. et al. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli. J. Clin. Endocrinol. Metab. 81, 909-913 (1996).
47. Reitschel, P. et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J. Clin. Endcocrinol. Metab. 86, 504-510 (2001).
48. Stanley, T. L. et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA 312, 380-389 (2014).
49. Bonewald, L. F., Kneissel, M. & Johnson, M. Preface: the osteocyte. Bone 54, 181 (2013).
50. Ducy, P. et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100, 197-207 (2000).
51. Esen, E. et al. WNT-LRP5 signaling induces Warburg effect through mTORC2 activation during osteoblast differentiation. Cell Metab. 17, 745-755 (2013).
52. Compton, J. & Lee, F. A review of osteocyte function and the emerging importance of sclerostin. J. Bone Joint Surg. Am. 96, 1659-1668 (2014).
53. Bonewald, L. F. & Wacker, M. J. FGF23 production by osteocytes. Pediatr. Nephrol. 28, 563-568 (2013).
54. Nakashima, T. et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 17, 1231-1234 (2011).
55. Ferron, M. et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142, 296-308 (2010).
56. Karsenty, G. in Cellular Endocrinology in Health and Disease Ch. 12 (eds Ulloa-Aguirre, A. & Conn, P. M.) 193-205 (Elsevier, 2014).
57. Rosen, C. J. & Klibanski. A. Bone, fat, and body composition: evolving concepts in the pathogenesis of osteoporosis. Am. J. Med. 122, 409-414 (2009).
58. Guntur, A. R., Le, P. T., Farber, C. R. & Rosen, C. J. Bioenergetics during calvarial osteoblast differentiation reflect strain differences in bone mass. Endocrinology 155, 1589-1595 (2014).
59. Esen, E. & Long, F. Aerobic glycolysis in osteoblasts. Curr. Osteoporos. Rep. 12, 433-438 (2014).
60. Cawthorn, W. P. et al. Bone marrow adipose tissue is an endocrine organ that contributes to increased circulating adiponectin during caloric restriction. Cell Metab. 20, 368-375 (2014).
61. Zimmet, P. Z., Magliano, D. J., Herman, W. H. & Shaw, J. E. Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol. 2, 56-64 (2014).
62. Guariguata, L. et al. Global estimates of diabetes prevalence in adults for 2013 and projections for 2035 for the IDF Diabetes Atlas. Diabetes Res. Clin. Pract. 103, 137-149 (2014).
63. Tuomi, T. et al. The many faces of diabetes: a disease with increasing heterogeneity. Lancet 383, 1084-1094 (2014).
64. Kahn, S. E., Cooper, M. E. & Del Prato, S. Pathophysiology and treatment of type 2 diabetes. Lancet 383, 1068-1083 (2014).
65. Murphy, R., Ellard, S. & Hattersley, A. T. Clinical implications of a molecular genetic classification of monogenic β-cell diabetes. Nat. Clin. Pract. Endocrinol. Metab. 4, 200-213 (2008).
66. Hall, S. S. A gene of rare effect. Nature 496, 152-155 (2013).
67. Zimmet, P. & Alberti, K. G. Surgery or medical therapy for obese patients with type 2 diabetes? N. Engl. J. Med. 366, 1635-1636 (2012).
68. Bernard, C. Lectures on the phenomena common to animals and plants (translated by Hoff, H. E., Guillemin, R. & Guillemin, L.) (Charles C. Thomas, 1974).
69. Adamovich, Y. Circadian clocks and feeding time regulate the oscillations and levels of hepatic triglycerides. Cell Metab. 19, 319-330 (2014).